AMPHOTERICIN B by Abbott is mechanism of action amphotericin b, the active ingredient of amphotericin b liposome for injection, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. First approved in 1996.
Drug data last refreshed 17h ago
Mechanism of Action Amphotericin B, the active ingredient of amphotericin B liposome for injection, acts by binding to the sterol component, ergosterol, of the cell membrane of susceptible fungi. It forms transmembrane channels leading to alterations in cell permeability through which monovalent…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
Deposition of Inhaled Liposomal Amphotericin B in Chronic Pulmonary Aspergillosis (CPA)
Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients
Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy
A Real-world Prospective Observational Study on the Efficacy and Safety of L-AmB(Liposomal Amphotericin B) for br- IFD(Breakthrough Invasive Fungal Disease) in Children and Adolescent Patients With Hematological Malignancies Receiving Triazoles or Echinocandins Prophylaxis
Worked on AMPHOTERICIN B at Abbott? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.